MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

ELUTIA INC. (ELUT)

ELUTIA INC. (ELUT)

|||

Cash Flow Overview

Change in Cash
-$8,592K
Free Cash flow
-$8,552K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Insurance receivables of litigat...
    • Stock-based compensation
    • Prepaid expenses and other
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Contingent liability for legal p...
    • Accounts payable and accrued exp...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-7,646
-7,469
70,791
-3,868
Depreciation and amortization
349
330
297
728
Gain on sale of orthobiologics business
0
425
80,211
-
Loss on early repayment of debt
-
-
-1,287
-
(gain) loss on revaluation of warrant liability
-226
1,655
-906
-5,098
Amortization of deferred financing costs and debt discount
-
-
-
54
Interest expense recorded as additional revenue interest obligation or long-term debt
140
145
-65
1,246
Stock-based compensation
905
931
872
1,982
Bad debt expense
-
-
458
-
Changes in right-of-use assets and lease liabilities and lease incentives received
88
320
-
-
Payments on revenue interest obligation
1,100
-
2,200
-
Other
-
-
-608
-
Accounts receivable
-630
334
-1,361
403
Inventory
-8
40
548
-239
Insurance receivables of litigation costs
-1,496
502
285
264
Prepaid expenses and other
-651
-241
2,183
-745
Accounts payable and accrued expenses
-1,358
542
-9,855
2,287
Contingent liability for legal proceedings
-2,398
-3,225
-5,142
-632
Other liabilities
-
-
1,068
97
Net cash used in operating activities
-8,461
-7,831
-24,814
-2,887
Proceeds from sale of orthobiologics business
0
425
80,435
-
Expenditures for property and equipment
91
459
854
630
Net cash used in investing activities
-91
-34
79,581
-630
Proceeds from public offering or private placement with warrants, net of offering costs
-
-
13,795
-
Proceeds from private placement and warrants, net of offering costs
-
-
-
0
Proceeds (repayments) of long-term debt, net
-
-
-23,064
-
Repayments of insurance premium financings
-
-
0
236
Payments for taxes upon vesting of restricted stock units
42
44
73
58
Proceeds from stock option exercises and issuance common stock under espp
2
47
0
32
Net cash provided by (used in) financing activities
-40
3
-23,138
-262
Net (decrease) increase in cash and cash equivalents
-8,592
-7,862
31,629
-3,779
Cash and cash equivalents, beginning of period
28,488
36,350
4,721
13,239
Cash and cash equivalents, end of period
19,896
28,488
36,350
4,721
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net (decrease)increase in cash and cash...-$8,592K (-81.30%↓ Y/Y)Insurance receivables oflitigation costs-$1,496K (-223.11%↓ Y/Y)Stock-based compensation$905K (-61.65%↓ Y/Y)Prepaid expenses andother-$651K (43.54%↑ Y/Y)Accounts receivable-$630K (-172.08%↓ Y/Y)Depreciation andamortization$349K (-80.17%↓ Y/Y)Interest expenserecorded as additional...$140K (-94.71%↓ Y/Y)Changes in right-of-useassets and lease...$88K Inventory-$8K (-100.60%↓ Y/Y)Proceeds from stockoption exercises and...$2K (-97.50%↓ Y/Y)Net cash used inoperating activities-$8,461K (50.55%↑ Y/Y)Net cash used ininvesting activities-$91K (76.79%↑ Y/Y)Net cash provided by(used in) financing...-$40K (-100.31%↓ Y/Y)Canceled cashflow$4,267K Canceled cashflow$2K Net loss-$7,646K (43.54%↑ Y/Y)Contingent liability forlegal proceedings-$2,398K (29.82%↑ Y/Y)Expenditures for property andequipment$91K (-76.79%↓ Y/Y)Payments for taxes uponvesting of restricted...$42K (-83.13%↓ Y/Y)Accounts payable andaccrued expenses-$1,358K (-233.01%↓ Y/Y)Payments on revenueinterest obligation$1,100K (gain) loss onrevaluation of warrant...-$226K (96.95%↑ Y/Y)